GMP Compliance – Not Investment – Impresses FDA, Chief Counsel Says
This article was originally published in The Tan Sheet
Executive Summary
Manufacturers should not expect FDA to back off from GMP enforcement actions simply because firms have increased their investment in compliance, FDA Chief Counsel Daniel Troy said during a recent University of Georgia GMP conference